NCT04673266 - Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Lymphoma PatientsThrombocytopenia

Interventions

DRUG

Romiplostim

All patients will begin weekly (+/- 2 days) romiplostim at 3 mcg/kg subcutaneously. The romiplostim dose will be titrated, based on weekly CBC/platelet counts.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Commack (All Protocol Activities), Commack

33136

University of Miami - Sylvester Comprehensive Cancer Center, Miami

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale